Myositis Treatment Market Share

  • Report ID: 3783
  • Published Date: Nov 20, 2025
  • Report Format: PDF, PPT

Myositis Treatment Market - Regional Analysis

North American Market Insights

The North America industry is expected to dominate majority revenue share of 37% by 2035. The growth of the market can be attributed majorly to the increasing frequency of musculoskeletal disorders amongst several people, backed by the sedentary lifestyle of individuals. For instance, it has been calculated that the prevalence of musculoskeletal diseases in the United States is approximately 124 million people which accounts for 1 out of every two persons. Further, the high health awareness amongst the population, along with easy access to quality healthcare in the developed region is attributed to rapid market expansion in the region during the forecast period. In addition, the region's expanding healthcare industry and rising healthcare expenditure are also anticipated to boost the market growth in the upcoming years.

APAC Market Insights

The Asia Pacific myositis treatment market, amongst the market in all the other regions, is projected to hold the second largest share of about 31% during the forecast period. The growth of the market can be attributed majorly to the increasing frequency of various chronic muscle diseases and prolonged pain, ache, and infection among the people living in the region. According to a report from the World Health Organization (WHO), more than 369 million people suffer from muscle-related diseases in the South-East Asia region. Furthermore, the burgeoning geriatric population in the region who are more prone to myositis and is expected to expand the market size in the analysis period. Also, the rising focus on health and fitness coupled with government initiatives that promote a healthy lifestyle is anticipated to increase the adoption rate of myositis treatment.

Europe Market Insights

Further, the market in Europe, amongst the market in all the other regions, is projected to hold a majority of the share by the end of 2035. The presence of a large pool of patients being diagnosed with various chronic and acute diseases leading to myositis is expected to increase the chances of myositis treatment in the upcoming years. Also, the high expenditure on health is anticipated to create a positive outlook for market growth in the region. Furthermore, the presence of favorable policies is anticipated to create a positive outlook for market expansion during the forecast period.

Myositis Treatment Market Share

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of myositis treatment is assessed at USD 753.47 million.

The global myositis treatment market size was valued at around USD 725.4 million in 2025 and is projected to grow at a CAGR of more than 4.3%, reaching USD 1.11 billion revenue by 2035.

By 2035, North America is poised to command a 37% share of the myositis treatment market during 2026-2035, supported by the escalating burden of musculoskeletal disorders.

Key players in the market include Baxter International, Inc., Eli Lilly and Company, Novartis AG, Sanofi-aventis Groupe, Abbott Laboratories, Johnson & Johnson Services, Inc., Merck & Co., Inc., Siemens Healthcare GmbH, Pfizer Inc., Becton, Dickinson and Company, IBSRELA, Indegene.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos